Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board
Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board
Protocol Title: The Effect of CBD Gum on Nausea and Vomiting During Pregnancy
协议标题:CBD口香糖对妊娠期恶心呕吐的影响
New York, NY, Dec. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a New York based diversified Life Sciences Company, today announced that it has formally submitted its Clinical Study Protocol ("Protocol") to the Institutional Review Board ("IRB"). The Company's Protocol Title: "The Effect of CBD Gum on Nausea and Vomiting During Pregnancy".
纽约,纽约,2021年12月17日(环球通讯社)--通过NewMediaWire--总部设在纽约的多元化生命科学公司Tauriga Sciences,Inc.(OTCQB:TAUG)(“Tauriga”或“公司”)今天宣布,它已向机构审查委员会(IRB)正式提交了其临床研究方案(“方案”)。该公司的协议标题:“CBD口香糖对妊娠期恶心呕吐的影响".
The purpose of this Clinical Study is: to examine the Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum.
这项临床研究的目的是:检查不同剂量大麻二醇对早孕期过度呕吐健康孕妇恶心频率和严重程度的影响及妊娠剧吐的诊断.
Hyperemesis Gravidarum is also known as: Morning Sickness
妊娠剧吐也被称为:晨吐
On December 16, 2021 the IRB acknowledged receipt of the Company's above-referenced Study Protocol (CIRBI Link: Pro00059685).
2021年12月16日,IRB确认收到公司的上述研究方案(CIRBI链接:Pro00059685)。
The IRB will begin Administrative Review of the Protocol Submission, and notify the Company if there are any clarifications required.
IRB将开始对提交的议定书进行行政审查,并在需要澄清时通知公司。
The Company's proposed Cannabidiol delivery system (via: sublingual absorption / oral mucosa) utilizes its proprietary Cannabidiol infused chewing gum platform. This focuses on Sublingual Delivery, which refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue. The Company expects to develop "mission critical" versions of its proprietary chewing gum, incorporating varying concentrations of CBD (potentially combined with other substances).
该公司建议的大麻二醇给药系统(通过:舌下吸收/口腔粘膜)利用其专有的大麻二醇口香糖平台。这项研究的重点是舌下给药,指的是物质通过舌下组织扩散到血液中的药理给药途径。该公司希望开发其专利口香糖的“关键任务”版本,包含不同浓度的CBD(可能与其他物质结合)。
ABOUT TAURIGA SCIENCES INC.
关于Tauriga Science Inc.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol ("CBD") and Cannabigerol ("CBG") Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company's commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: ). Please visit our corporate website, for additional information, as well as inquiries, at
Tauriga Sciences,Inc.(TAUG)是一家创收的多元化生命科学公司,从事几项主要的商业活动和计划。该公司制造和分销多个专有零售产品和产品线,主要集中在大麻二醇(“CBD”)和大麻酚(“CBG”)食用细分市场。主要产品线,品牌为金牛胶™,由一个专有的补充剂口香糖,这是犹太认证,清真认证,素食配方(CBD注入金牛胶™口味:薄荷,血橙,石榴),(CBG注入金牛胶™口味:桃子柠檬,黑加仑),(台达8THC注入金牛胶™口味:常绿薄荷),(该公司的商业化战略包括广泛的零售客户、分销商和快速增长的电子商务业务部门(电子商务网站:)。如需更多信息和查询,请访问我们的公司网站,网址为
Complementary to the Company's retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled "MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT". On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
与该公司零售业务相辅相成的是其正在进行的药品开发计划。这涉及到开发一种建议的药学级版本的Tauri-Gum™,用于调节恶心(专门为以下适应症设计:正在接受化疗的患者)。2021年3月22日,该公司宣布已将其美国临时专利申请(于2020年3月17日提交)转换为美国非临时专利申请。向美国专利商标局提交的这项专利的标题是“药物CBD组合物、制造方法和治疗方法”。2020年12月18日,该公司披露,它已经与CSTI签订了一项主服务协议,以领导公司的临床开发工作。
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
该公司总部设在纽约州瓦平格斯福尔斯。此外,该公司还运营着两个全职电子商务履行中心:一个位于德克萨斯州的蒙哥马利,另一个位于纽约的布鲁克林。
DISCLAIMER -- Forward-Looking Statements
免责声明--前瞻性声明
This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management's beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as "may," "will," "expects," "anticipates," believes, "hopes," "believes," or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management's present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the "Risk Factors" section of Tauriga's Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
本新闻稿包含1995年“私人证券诉讼改革法”所界定的某些“前瞻性陈述”,这些陈述代表管理层对未来事件的信念和假设。这些前瞻性陈述通常使用诸如“可能”、“将会”、“预期”、“预期”、“相信”、“希望”、“相信”或“计划”等词语来表示,可能包括有关公司目标以及某些公司目标和里程碑的实现情况的陈述。前瞻性陈述基于当前情况以及管理层目前对尚未发生、可能发生或可能发生的事件的信念,这些事件的后果或时机与现在假设或预期的不同。由于已知和未知的风险和不确定性,实际结果可能与前瞻性陈述中表述的大不相同,例如不能保证一般的经济和商业条件,成功开发和销售产品的能力,消费者和企业的消费习惯,完成成功的收购和许可交易的能力,汇率的波动,以及Tauriga几乎或无法控制的其他因素。其中许多风险和不确定性在Tauriga公司的10-K表格和其他不定期提交给证券交易委员会的文件中的“风险因素”部分有更详细的讨论。此类前瞻性陈述仅在本新闻稿发布之日作出,Tauriga不承担更新前瞻性陈述以反映后续事件或情况的义务。您不应该过分依赖这些前瞻性陈述。
Contact:
联系方式:
Tauriga Sciences, Inc.
Tauriga Sciences,Inc.
4 Nancy Court, Suite 4
南希苑4号套房
Wappingers Falls, NY 12590
纽约州瓦平格斯福尔斯,邮编:12590
Chief Executive Officer
首席执行官
Mr. Seth M. Shaw
Seth M.Shaw先生
Email: sshaw@tauriga.com
电子邮件:sshaw@tauriga.com
cell # (917) 796 9926
电话号码:(917)7969926
Company Instagram: @taurigum
公司Instagram:@taurigum
Personal Instagram: @sethsms47
个人Instagram:@sethsms47
Twitter: @SethMShaw
推特:@SethMShaw
Corp. Website:
公司网站:
E-Commerce Website:
电子商务网站: